NHSi’s research activities to date have focused on validating the NHSi technology
approach, building a robust and statistically significant reference database, and
conducting efficacy studies in key disease indications.
The table below itemizes the trials that NHSi has completed to date to validate
the clinical utility of the HVA technology.
| Trial |
Institution |
Subjects |
| Asymptomatic Reference Population |
Wake Forest University |
364 |
| Normal Pressure Hydrocephalus |
Cleveland Clinic |
30 |
| Carotid Artery Disease |
Columbia Presbyterian Hospital |
50 |
| Sleep Apnea (registry data) |
Beta customer site |
~1000 |
| Drug Response |
Major pharmaceutical company |
16 |
| Cognitive Impairment / Pediatric Oncology |
Wake Forest University |
15 |
| Alzheimer’s Disease |
University of North Texas |
87 |
| Sickle Cell Disease |
Wake Forest University |
80 |
| Sports-Related Concussive Head Injury |
Wake Forest University |
215 |
| Normal Pressure Hydrocephalus (pilot data) |
New Health Sciences |
58 |
| Carotid Artery Disease (Stent) (pilot data) |
University of Houston |
9 |
| Altitude Sickness |
USUHS (US military) |
9 |